Revolutionary Collaboration on Brain Disease Treatment
Remed, a leading manufacturer of transcranial magnetic stimulation (TMS), has joined forces with prestigious research institutes in Daegu to tackle intractable brain diseases. Together, they are conducting groundbreaking research aimed at treating cerebellar ataxia, a condition that leads to stumbling and hand tremors due to cerebellar dysfunction.
Exploratory Clinical Trials Underway
Under the leadership of K-Medi Hub, a research initiative has been launched with the goal of restoring balance in patients with cerebellar ataxia through magnetic stimulation treatment. This collaborative effort involves Chilgok Kyungpook National University Hospital, Korea Brain Research Institute, and Remed Co., Ltd.
Cerebellar ataxia is a debilitating condition characterized by balance and speech disorders, often with no available treatment options. However, recent developments in transcranial magnetic stimulation have shown promise in improving motor function in patients with this condition.
Pioneering Clinical Protocol Development
The exploratory clinical trial aims to evaluate the effectiveness of transcranial magnetic stimulation in improving gait and balance in patients with cerebellar ataxia. This groundbreaking initiative has received approval under the Food and Drug Administration Clinical Research Scheme (IDE).
Leading experts from Chilgok Kyungpook National University Hospital, Korea Brain Research Institute, and K-Medi Hub are spearheading this research, with the support of cutting-edge magnetic stimulation devices provided by Remed Co., Ltd.
Expansion of Treatment Indications
Remed Co., Ltd. plans to leverage the findings of this research to broaden the indications for transcranial magnetic stimulation, building upon its existing approval for the treatment of depression. This strategic partnership marks a significant step towards addressing previously untreatable diseases.
Yang Jin-young, Chairman of K-Medi Hub, emphasized the importance of securing evidence for the effectiveness of cerebellar ataxia treatment and the potential for groundbreaking advancements in medical treatment.
As this pioneering collaboration continues to push the boundaries of medical research, the pursuit of innovative solutions for previously incurable diseases remains a top priority for all involved parties.
Copyright © JOBPOST. Reproduction and redistribution prohibited.
Remed, a major TMS manufacturer, and major research institutes in Daegu are teaming up to treat intractable brain diseases.
Panoramic view of K Medi Hub (photo provided / K Medi Hub)
[잡포스트] Correspondent Koo Woong = K-Medi Hub is conducting research to restore the sense of balance through magnetic stimulation treatment in patients with cerebellar ataxia, who exhibit symptoms of stumbling and hand tremors due to cerebellar dysfunction.
The Institute’s Advanced Medical Device Development Support Center began exploratory clinical trials on patients with cerebellar ataxia using transcranial magnetic stimulation on November 23 with Chilgok Kyungpook National University Hospital, Korea Brain Research Institute, and Remed Co, Ltd through joint research and development through his own research project. he did
Remed greatly appreciates K-Medi Hub’s expertise in supporting medical device commercialization, Chilgok Kyungpook National University Hospital’s differential treatment results for degenerative cranial nerve diseases, and Korea Brain Research Institute’s excellent research capabilities, and has entered into an unusual partnership with region outside the metropolitan area to conduct research.
Cerebellar ataxia is a genetic or acquired condition that causes dysfunction in the cerebellum, causing symptoms such as balance disorders, eye movement disorders, and speech disorders. Stumbling when walking, shaking hands, or losing your grip. So far, it is known that there is no way to treat the disease itself fundamentally, and the disease is managed through rehabilitation exercises.
Recently, transcranial magnetic stimulation (TMS), a type of non-invasive brain stimulation, has been used not only for rehabilitative exercise therapy but also for the restoration of impaired motor function in patients with cerebellar ataxia, but clinical trials that have started using it again. Korea There are no enemies. K-Sedi Hub magnetic stimulation treatment is the first of its kind in Korea.
This exploratory clinical trial will study whether treatment using transcranial magnetic stimulation is effective in improving gait and balance in patients with cerebellar ataxia, and will be conducted with Food and Drug Administration Clinical Research Scheme (IDE) approval .
The study is supervised by Kang Bong-geun, a senior researcher at the K Medi Hub Advanced Medical Device Development Support Center, and was jointly participated by Professor Ho-won Lee from the Department of Neurology of Chilgok Kyungpook National University Hospital, Professor Eun-hee Park . the Department of Rehabilitation Medicine, and Senior Researcher Min-young Jeong of the Korean Brain Research Institute.
The aim of the research is to develop a clinical protocol for the treatment of gait disorders by collecting and analyzing brain signals after magnetic stimulation of the brain in exploratory clinical trials, and to secure evidence of effectiveness by collecting and analyzing the brain signal.
The magnetic stimulation device is provided by Remed Co., Ltd. Remed Co., Ltd has already received approval from the Ministry of Food and Drug Safety for TMS for the treatment of depression, and plans to expand the indications through this KMediHub support project.
Yang Jin-young, Chairman of K-Medi Hub, said, “We are working with a company that treats depression with TMS (a treatment that stimulates the brain with a magnetic field to activate cells) and secure evidence for the effectiveness of cerebellar ataxia treatment .” He added, “This support is for existing approved medical treatment.” “This is the first case where K-Medi Hub supports clinical trials to expand the indications for the device, and we will strive to continue to pay attention to the treatment of incurable diseases.”
Copyright © JOBPOST Reproduction and redistribution prohibited.
#clinical #study #treatment #convulsive #cerebellar #ataxia
